Welcome to our dedicated page for AETHLON MEDICAL SEC filings (Ticker: AEMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aethlon Medical, Inc. filings document the regulatory record of a Nevada clinical-stage medical device company developing the investigational Aethlon Hemopurifier. Form 8-K reports cover quarterly financial results furnished under Regulation FD, material agreements tied to securities purchase arrangements, warrant-related capital-structure updates, and approved changes to the company's equity incentive plan.
Proxy materials cover annual-meeting and stockholder voting matters, including governance and compensation-plan proposals. Registration statements describe securities offered for sale, share-capital terms and related offering mechanics for the company's common stock and other securities.
Aethlon Medical, Inc. (AEMD) is asking stockholders to vote at a virtual annual meeting on October 1, 2026. Key items include electing five directors, ratifying Haskell & White LLP as auditor, and an advisory vote on executive pay.
Major capital-structure proposals seek approval to issue up to 1,126,602 shares of common stock upon exercise of warrants from the July 2026 offering, increase authorized common stock from 20,000,000 to 200,000,000 shares, and authorize 20,000,000 shares of preferred stock with series terms set by the board. Additional proposals would pre-approve share issuances for future private financings and warrant exercise inducement transactions, expand the 2020 Equity Incentive Plan by 100,000 shares, and permit meeting adjournment to solicit more proxies. Stockholders of record on August 10, 2026 (711,136 shares outstanding) may vote.
AETHLON MEDICAL INC (AEMD) reported an update on its capital structure. Following recent exercises of certain pre-funded warrants, the company has 1,604,095 shares of common stock outstanding as of the close of business on August 28, 2026. The company states that, as a result of these exercises, all previously outstanding pre-funded warrants have been exercised, leaving no such warrants remaining outstanding.
AETHLON MEDICAL, INC. (AEMD) is calling a virtual annual stockholder meeting on October 1, 2026, with a record date of August 10, 2026, when 711,136 common shares were outstanding. Stockholders will elect five directors and vote on ratifying Haskell & White LLP as auditor for the year ending March 31, 2027, and an advisory say‑on‑pay for named executive officers.
Major capital structure proposals include approval, under Nasdaq Listing Rule 5635(d), of up to 1,126,602 common shares issuable upon exercise of July 2026 offering warrants, an increase in the 2020 Equity Incentive Plan reserve by 100,000 shares, an amendment to raise authorized common stock from 20,000,000 to 200,000,000 shares, and authorization of 20,000,000 shares of preferred stock with series terms set by the board. Additional proposals seek advance approval for future private financings and warrant exercise inducement transactions, plus the ability to adjourn the meeting if more proxies are needed.
Aethlon Medical, Inc. reported another quarter as a clinical-stage company with no revenue, focused on developing its Hemopurifier immunotherapeutic device for oncology and life‑threatening viral infections. A Phase 1 oncology trial in Australia is ongoing at three sites, and Cohort 3 has begun enrollment.
For the three months ended June 30, 2026, operating expenses were $1.6 million, down from $1.8 million a year earlier, and the net loss narrowed to $1.55 million from $1.76 million. Research and development expenses were $549,000, reflecting continued investment in the Hemopurifier program.
At June 30, 2026, cash and cash equivalents were $4.93 million, total assets $6.24 million, and all liabilities were current at $1.04 million, resulting in stockholders’ equity of $5.20 million. The company raised approximately $1.9 million in gross proceeds via its at‑the‑market equity program during the quarter and subsequently completed a registered offering of about $4.0 million, plus a 1‑for‑5 reverse stock split effective July 31, 2026. Management states that existing cash, together with recent financings, is expected to fund planned operations for at least twelve months, though additional capital will likely be required to advance development beyond that period.
Aethlon Medical, Inc. reported fiscal first-quarter 2027 results for the quarter ended June 30, 2026 and provided an update on its Hemopurifier program. Clinically, the company dosed the first participant in the third and final cohort of its Phase 1 oncology study in Australia. Early observations from the first two cohorts showed consistent decreases in tumor-derived extracellular vesicles and cancer‑linked microRNAs and signs of immune changes; these findings are preliminary and will be fully evaluated after study completion. A Long COVID manuscript describing extracellular vesicles in patients was accepted for publication, showing that these vesicles bind to the Hemopurifier’s GNA affinity resin.
Cash and cash equivalents were approximately $4.9 million as of June 30, 2026. Subsequent to quarter‑end, the company raised about $4.0 million in gross proceeds via a public offering and believes its cash resources can fund operations for at least the next 12 months. Consolidated operating expenses decreased 11.9% to about $1.6 million from $1.8 million in the prior‑year quarter, and operating loss narrowed accordingly. Net loss attributable to common stockholders was $1.55 million, or $4.02 per share, compared with $1.76 million, or $42.42 per share, a year earlier.
Aethlon Medical Inc. has three reporting persons – Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC – who report beneficial ownership of its common stock through a warrant position. As of the close of business on June 30, 2026, they may be deemed to beneficially own 55,556 shares of common stock issuable upon exercise of a warrant held by Intracoastal (the “Intracoastal Warrant”). This stake represents approximately 2.3% of Aethlon Medical’s common stock.
The percentage is based on 2,370,560 shares of common stock outstanding as of June 8, 2026, plus the 55,556 warrant shares. All 55,556 shares are reported with shared voting and dispositive power, and no shares are held with sole voting or dispositive power. The reporting group indicates ownership of 5 percent or less of the class.
Aethlon Medical, Inc. approved a 1-for-5 reverse stock split of its issued and outstanding common stock through a Certificate of Change filed under Nevada law. The company cites this move as part of its capital-markets and operating plan, including dilution management and continued compliance with Nasdaq Listing Rule 5550(a)(2).
The reverse split will be effective at 10:00 a.m. Eastern Time on July 31, 2026, with AEMD shares expected to begin trading on a split-adjusted basis on August 4, 2026 under the same symbol and a new CUSIP of 00808Y703. Every five pre-split shares will be combined into one share, with no cash paid for fractional shares; instead, any fractional entitlement will be rounded up to one whole post-split share.
Authorized common stock will decrease from 100,000,000 to 20,000,000 shares. Based on 3,249,569 shares outstanding as of July 23, 2026, there will be approximately 649,914 shares outstanding after the split, subject to rounding. The company states that each holder’s percentage ownership and voting power will remain virtually unchanged, preferred stock authorization is unaffected, and outstanding options, warrants and convertible securities will be adjusted proportionately. Under Nevada statutes, the board approved the transaction without a stockholder vote.
Aethlon Medical, Inc. entered into a securities purchase agreement and priced a follow-on offering of approximately $4.0 million, selling 5,633,009 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 5,633,009 shares at $0.7101 per share (or pre-funded warrant) and accompanying warrant. The offering, priced at-the-market under Nasdaq rules, is expected to close on or about July 7, 2026, with Maxim Group LLC as sole placement agent. Aethlon expects net proceeds of about $3.335 million after fees and expenses, which it plans to use mainly for general corporate purposes including research and development, clinical trials, capital expenditures, and working capital. Company officers and directors agreed to 90-day lock-ups, and Aethlon accepted restrictions on additional equity issuances for up to one year, subject to specified exceptions.
Aethlon Medical, Inc. is offering 263,000 shares of common stock, pre-funded warrants to purchase 5,370,009 shares and common warrants to purchase 5,633,009 shares at a combined public offering price of $0.71 per share (or pre-funded warrant) and accompanying warrant. The offering also registers the 11,228,338 shares issuable upon exercise of the warrants, pre-funded warrants and placement agent warrants. The offering is structured on a best-efforts basis with no minimum and includes placement agent warrants equal to 4% of shares issued. Common warrants have a $0.71 exercise price and will be exercisable upon stockholder approval or earlier if specified Pricing Conditions are met. Proceeds examples in the prospectus show a maximum public offering amount of $4,000,000 and estimated proceeds before expenses of $3,740,000. The company discloses material risks including substantial doubt about its ability to continue as a going concern and Nasdaq continued-listing risks.